Skip to search formSkip to main contentSkip to account menu

tesamorelin

Known as: GHRH(1-44), N-[(3E)-1-oxo-3-hexenyl]Somatoliberin (human pancreatic islet) 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (2)

EgriftaTH9507

Broader (1)

Somatotropin-Releasing Hormone
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.
2015
2015
Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat
Background Tesamorelin, a synthetic analog of human growth hormone-releasing factor, decreases visceral adipose tissue (VAT) in… 
2015
2015
Population Pharmacokinetic Analysis of Tesamorelin in HIV-Infected Patients and Healthy Subjects
Background and ObjectivesTesamorelin is a synthetic analogue of growth hormone-releasing factor (GRF), which increases basal and… 
Review
2013
Review
2013
Tesamorelin for the treatment of excess abdominal fat in HIV-infected individuals with lipodystrophy
Metabolic and morphologic abnormalities in persons with HIV remain common contributors to stigma and morbidity. Increased… 
2012
2012
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.
BACKGROUND Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose tissue (VAT) by 15%-20% over 6-12… 
2011
2011
Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction
Objective:To report the effects of tesamorelin, a growth hormone-releasing hormone analogue, on inflammatory and fibrinolytic… 
2011
2011
Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.
2011
2011
Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy
Morphologic and metabolic abnormalities remain a common problem in patients with HIV-1 infection, which contributes to poor self… 
2010
2010
FDA approves tesamorelin for HIV-related lipodystrophy.
FDA on November 10 announced the approval of tesamorelin, a once-daily injectable treatment to reduce excess abdominal fat in HIV… 
Review
2009
Review
2009
Tesamorelin, a human growth hormone releasing factor analogue
Background: The combination of clinical effectiveness with a variety of adverse side effects from the use of recombinant human… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)